TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Akebia Therapeutics
Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Akebia Therapeutics presented a post-hoc win-odds analysis of vadadustat in dialysis patients, demonstrating statistically significant favorable outcomes compared to darbepoetin alfa in mortality and hospitalization metrics.

Insights
PM   positive

Successfully transitioning to smoke-free products, strong growth in nicotine pouches and heated tobacco, recent significant dividend increase of 8.9%, and promising trajectory in replacing traditional cigarette revenues


AKBA   positive

Presented favorable clinical trial data showing statistically significant benefits of their drug vadadustat in treating anemia in dialysis patients, potentially improving treatment standards